Andrew Warwick Hamer Purchases 18,900 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) Senior Officer Andrew Warwick Hamer bought 18,900 shares of the business's stock in a transaction dated Thursday, December 19th. The shares were acquired at an average cost of C$1.88 per share, for a total transaction of C$35,606.69.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock opened at C$1.81 on Wednesday. The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07. Cardiol Therapeutics Inc. has a 52 week low of C$1.09 and a 52 week high of C$4.26. The firm's 50 day moving average is C$2.34 and its two-hundred day moving average is C$2.67. The firm has a market capitalization of C$126.48 million, a P/E ratio of -4.11 and a beta of 0.70.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Read More

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Cardiol Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Cardiol Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles